Revealed: Our 'Shadow Investing' Secret for Small Cap Stocks
Here is the latest financial fact sheet of SEQUENT SCIENTIFIC. For more details, see the SEQUENT SCIENTIFIC quarterly results and SEQUENT SCIENTIFIC share price. For a sector overview, read our pharmaceuticals sector report.
1 Day | % | 0.2 |
No. of shares | m | 249.48 |
1 Week | % | -1.2 |
1 Month | % | -2.6 |
1 Year | % | 46.7 |
52 week H/L | Rs | 155.5/70.2 |
No. of Mths Year Ending |
12 Mar-19* |
12 Mar-20* |
12 Mar-21* |
12 Mar-22* |
12 Mar-23* |
5-Yr Chart Click to enlarge
|
---|
SEQUENT SCIENTIFIC EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 89 | 99 | 265 | 336 | 156 | |
Low | Rs | 42 | 52 | 70 | 121 | 62 | |
Sales per share (Unadj.) | Rs | 42.1 | 47.5 | 54.8 | 56.9 | 57.0 | |
Earnings per share (Unadj.) | Rs | 2.3 | 3.3 | 4.2 | 1.8 | -4.9 | |
Diluted earnings per share | Rs | 2.3 | 3.3 | 4.2 | 1.8 | -4.9 | |
Cash flow per share (Unadj.) | Rs | 4.0 | 5.3 | 6.2 | 3.9 | -2.7 | |
Dividends per share (Unadj.) | Rs | 0.20 | 0 | 0.50 | 0 | 0 | |
Adj. dividends per share | Rs | 0.20 | 0.00 | 0.50 | 0.00 | 0.00 | |
Avg Dividend yield | % | 0.3 | 0 | 0.3 | 0 | 0 | |
Book value per share (Unadj.) | Rs | 27.9 | 27.1 | 29.0 | 26.0 | 25.8 | |
Adj. book value per share | Rs | 27.6 | 27.0 | 28.9 | 25.9 | 25.8 | |
Shares outstanding (eoy) | m | 246.87 | 248.37 | 248.37 | 248.37 | 249.43 | |
Price / Sales ratio | x | 1.6 | 1.6 | 3.1 | 4.0 | 1.9 | |
Avg P/E ratio | x | 28.5 | 22.9 | 39.8 | 126.9 | -22.3 | |
P/CF ratio (eoy) | x | 16.4 | 14.2 | 26.8 | 59.0 | -41.0 | |
Price / Book Value ratio | x | 2.4 | 2.8 | 5.8 | 8.8 | 4.2 | |
Dividend payout | % | 8.7 | 0 | 11.9 | 0 | 0 | |
Avg Mkt Cap | Rs m | 16,226 | 18,795 | 41,590 | 56,802 | 27,151 | |
Total wages/salary | Rs m | 1,459 | 1,651 | 1,872 | 2,314 | 2,584 |
SEQUENT SCIENTIFIC INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 10,393 | 11,792 | 13,616 | 14,128 | 14,209 | |
Other income | Rs m | 87 | 101 | 105 | 109 | 64 | |
Total revenues | Rs m | 10,480 | 11,893 | 13,721 | 14,237 | 14,273 | |
Gross profit | Rs m | 1,249 | 1,703 | 2,011 | 1,094 | -528 | |
Depreciation | Rs m | 419 | 506 | 506 | 515 | 557 | |
Interest | Rs m | 328 | 357 | 244 | 158 | 355 | |
Profit before tax | Rs m | 589 | 941 | 1,366 | 529 | -1,377 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Tax | Rs m | 20 | 120 | 322 | 82 | -157 | |
Profit after tax | Rs m | 569 | 820 | 1,045 | 448 | -1,220 | |
Gross profit margin | % | 12.0 | 14.4 | 14.8 | 7.7 | -3.7 | |
Effective tax rate | % | 3.4 | 12.8 | 23.6 | 15.4 | 11.4 | |
Net profit margin | % | 5.5 | 7.0 | 7.7 | 3.2 | -8.6 |
SEQUENT SCIENTIFIC BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 6,061 | 7,243 | 7,667 | 8,084 | 8,125 | |
Current liabilities | Rs m | 4,404 | 5,149 | 5,131 | 5,374 | 5,588 | |
Net working cap to sales | % | 15.9 | 17.8 | 18.6 | 19.2 | 17.9 | |
Current ratio | x | 1.4 | 1.4 | 1.5 | 1.5 | 1.5 | |
Inventory Days | Days | 97 | 59 | 31 | 27 | 21 | |
Debtors Days | Days | 98 | 99 | 93 | 85 | 88 | |
Net fixed assets | Rs m | 7,960 | 7,389 | 6,763 | 6,782 | 7,435 | |
Share capital | Rs m | 494 | 497 | 497 | 497 | 499 | |
"Free" reserves | Rs m | 6,384 | 6,233 | 6,702 | 5,953 | 5,926 | |
Net worth | Rs m | 6,878 | 6,730 | 7,199 | 6,450 | 6,425 | |
Long term debt | Rs m | 1,478 | 1,501 | 937 | 1,225 | 1,828 | |
Total assets | Rs m | 14,021 | 14,632 | 14,430 | 14,866 | 15,661 | |
Interest coverage | x | 2.8 | 3.6 | 6.6 | 4.4 | -2.9 | |
Debt to equity ratio | x | 0.2 | 0.2 | 0.1 | 0.2 | 0.3 | |
Sales to assets ratio | x | 0.7 | 0.8 | 0.9 | 1.0 | 0.9 | |
Return on assets | % | 6.4 | 8.0 | 8.9 | 4.1 | -5.5 | |
Return on equity | % | 8.3 | 12.2 | 14.5 | 6.9 | -19.0 | |
Return on capital | % | 11.0 | 15.8 | 19.8 | 9.0 | -12.4 | |
Exports to sales | % | 0 | 2.7 | 5.0 | 2.2 | 1.8 | |
Imports to sales | % | 0 | 1.1 | 2.1 | 1.6 | 1.0 | |
Exports (fob) | Rs m | 0 | 316 | 686 | 311 | 255 | |
Imports (cif) | Rs m | 0 | 130 | 281 | 220 | 138 | |
Fx inflow | Rs m | 0 | 316 | 686 | 311 | 255 | |
Fx outflow | Rs m | 0 | 130 | 281 | 220 | 138 | |
Net fx | Rs m | 0 | 185 | 405 | 91 | 117 |
SEQUENT SCIENTIFIC CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 1,160 | 1,153 | 1,148 | 306 | 168 | |
From Investments | Rs m | -677 | -723 | 96 | -956 | -650 | |
From Financial Activity | Rs m | -201 | -428 | -1,388 | 673 | 322 | |
Net Cashflow | Rs m | 282 | 3 | -144 | 38 | -159 |
Share Holding
Shareholding as on Mar 2024
|
Company Information
|
CHM: Kamal K Sharma | COMP SEC: Krunal Shah | YEAR OF INC: 1985 | BSE CODE: 512529 | FV (Rs): 2 | DIV YIELD (%): - |
More Pharmaceuticals Company Fact Sheets: DIVIS LABORATORIES DR. REDDYS LAB CIPLA ZYDUS LIFESCIENCES SUN PHARMA
Compare SEQUENT SCIENTIFIC With: DIVIS LABORATORIES DR. REDDYS LAB CIPLA ZYDUS LIFESCIENCES SUN PHARMA
Indian share markets ended the mock trading session on a positive note tracking strong global peers and FII inflows.